downgrad ew earn
downgrad share ow ew
lower pt reduct
ep plan exit upjohn expos lower-than-
expect earn remainco innov
busi upjohn patent busi spun
thesi would outperform due improv prospect
invalid re-set earn side busi pfizer
announc exit upjohn busi real news weaker
underli earn remainco innov newco anticip
thu downgrad share ow ew
although view upjohn exit strateg sound deal new
manag disclosur reveal earn power much weaker
realiz factor includ prevnar xeljanz pressur due recent
synergi upjohn exit weaker upjohn financi includ china price
cut pressur continu report result includ upjohn
deal close lower revenu
adj ep
cut pt prior pt base upon
ep new pt two compon pfizer remainco
innov remainco ep share newco
upjohn remainco higher qualiti busi thu
warrant higher price-to-earnings believ appropri given current
pharmaceut sector landscap pt impli price-to-earnings multipl
ep unadjust upjohn exit
math new pt exhibit indic expect remainco
innov busi revenu pre-tax margin
assum tax rate estim net incom share
buy-back yield ep million share
newco estim ev pro forma ebitda
net debt yield equiti valu share price base
major pharmaceut unit state america
unless otherwis note metric base modelwar
consensu data provid thomson reuter estim
seek busi
compani cover morgan stanley research
result investor awar firm may
conflict interest could affect object
morgan stanley research investor consid
morgan stanley research singl factor make
invest decis
analyst certif import disclosur
refer disclosur section locat end
share count million exhibit sharehold would receiv
share newco share impli per share valu believ
ev/ebitda multipl newco warrant trade
ebitda prior deal announc expect newco
modest growth prospect dividend yield lower leverag improv
corpor govern remov dutch sticht
equal-weight share although
anticip solid growth prospect see
stock fairli valu
project revenu growth
ep growth
grow pipelin could
drive addit investor enthusiasm
given financi complex could
upward/downward surpris associ
upjohn exit innov stand-alon
ep newco
ep newco
pipelin newsflow surprisingli encourag earn higher
anticip upjohn exit valuabl ibranc adjuv trial succeed
interim look late late-stag pipelin readout compel ep
forecast driven new product sale upsid addit share
repurchas upjohn exit valuabl anticip
revenu earn result rel
prevnar infant phase result
updat plan move phase
ibranc growth driver perform
ep newco
ep newco
deliv financi in-lin manag target valuat
upjohn-myl newco ebitda project mid-high singl digit
revenu low doubl digit ep growth base assum
prevnar infant move phase ibranc adjuv phase
succe assum remain innov busi
ep newco
ep newco
shortfal occur pipelin disappoint upjohn exit less valuabl
product revenu face competit price pressur drive ep
downsid prevnar phase infant data surprisingli support
move phase ibranc adjuv phase trial fail price-to-earnings
contract due financi pressur plu pipelin failur
polit action us drug price
risk achiev price
upsid risk core busi upsid
extern transact boost
downsid risk revenu shortfal
associ upjohn exit price-to-earnings contract due
pipelin disappoint legal
disappoint neg us drug price
sharehold would newco sharehold expect
receiv share newco share
exhibit reconcili pfe/myl share newco calcul
consist notion share today remainco share share newco
exhibit valuat newco upjohn remainco innov
new pfizer disclosur impli lower earn power
guid manag provid follow target
innov busi revenue pre-tax margin upjohn revenue
adj ebitda
new revenu forecast project includ innov
revenu vs manag target approxim upjohn revenu
vs manag target
prevnar phase infant readout soon assum move
expect phase infant proof-of-concept result support advanc
phase poc trial includ arm hope safeti profil
roughli similar anticip success given core
pneumococc conjug vaccin expertis pfizer ir state result
disclos data surprisingli disappoint would neg impact
merck develop pneumococc vaccin cover two serotyp
prevnar howev also develop follow-on
cover five serotyp merck
merck phase data suggest higher serotyp immun respons prevnar
may necessarili translat better protect clinic outcom merck
shown compar immun reaction head-to-head vs prevnar
share serotyp except serotyp show higher immun
reaction accord acip slide serotyp caus remain prevnar-
type diseas burden us countri use prevnar howev believ
fda cdc would give claim better outcom base
exhibit merck show higher immun reaction prevnar serotyp
expect file adult could month behind
merck adult file three phase adult trial
expect complet date dec
jan merck schedul conclud phase adult trial pneu-flu
pneu-path june decemb
infant appear roughli year behind merck infant time
await poc data mid-year poc data posit expect pfizer could start phase
infant trial earli merck infant trial start dec june
complet expect jan dec respect
breadth coverag like drive adopt view launch short
time would unlik impact sale long term
exhibit battl pneumococc vaccin
present
earli
infant trial take longer adult trial infant receiv four dose adult receiv one
ibranc adjuv readout
project ibranc grow includ
approxim sale adjuv ibranc approv metastat
breast cancer conduct phase adjuv post surgeri outcom trial
broaden indic earli stage breast cancer current model global ibranc
sale project increment early-stag breast
cancer plu exist indic ex-u growth yield ibranc
could captur vast major market share earli stage breast cancer
rel clean safeti profil rel competitor think adjuv breast
cancer patient would want avoid kisqali nv cardiovascular risk verzenio
phase adjuv surgeri outcom trial palla penelope-b set
report late palla compar ibranc two year standard
endocrin therapi vs standard endocrin therapi patient
earli stage stage breast cancer primari endpoint invas diseas free
surviv idf treatment durat least five year palla estim
primari final complet sept sept penelope-b compar
ibranc month standard anti-hormon therapi vs standard anti-hormon
therapi patient earli stage breast cancer high-risk
relaps neo-adjuv chemotherapi surgeri henc think repres
smaller opportun palla primari endpoint idf estim primari
final complet decemb novemb importantli breast cancer
expert host physician panel day januari state
believ palla penelope-b sized/design appropri
competitor drug side effect issu could limit uptak adjuv
breast see limit competit threat ibranc early-stag breast cancer given
side effect issu early-stag patient may toler novarti kisqali carri
cardiovascular risk lilli verzenio carri diarrhea risk novarti kisqali phase
trial high risk adjuv breast cancer primari final
complet date march lilli verzenio phase monarch trial
high risk stage adjuv breast cancer primari final complet date
april june
price
price
price
compani data thomson reuter morgan stanley research valuat methodolog risk associ price target referenc research report pleas contact client support follow
us/canada hong kong latin america london singapor sydney tokyo altern may
contact invest repres morgan stanley research broadway attent research manag new york ny usa indic data compani remov
consider polici and/or applic regul may preclud issu inform respect compani time
us major pharma includ
sg sale
 sale
short-term
a/p accru liabil
total liabil s/e
chang work capit
oper
invest
net chang debt
financ
net chang cash
act financi advisor inc relat
agreement glaxosmithklin plc glaxo creat global consum healthcar
compani contribut consum healthcar busi glaxo
exist consum healthcar busi announc decemb propos
joint ventur subject customari close condit includ regulatori approv
agre pay fee servic includ transact fee
conting upon consumm propos transact pleas refer
note end report
current act financi advisor inc respect
definit merger agreement acquir array biopharma inc
array announc june agreement subject consumm
tender offer share array requir regulatori approv customari
close condit report inform provid herein also intend
provid advic respect tender offer ii serv endors tender
offer iii result procur withhold revoc tender
exchang action secur holder agre pay fee morgan
stanley financi servic includ transact fee conting upon
consumm transact pleas refer note end report
